• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

XyloCor Therapeutics

Monday, June 03, 2024
CP
Cardiovascular
XyloCor Therapeutics, Inc. is a private, clinical stage biopharmaceutical company developing potential best in class gene therapies to transform outcomes for patients with cardiovascular disease. There are 10.8 million patients in the United States with chronic stable angina, of which 1.4 million are refractory angina patients with no remaining treatment options. The Company’s lead gene therapy candidate is XC001, which is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow. By restoring blood flow, chest pain associated with refractory angina should decrease, potentially improving patients’ quality of life by enabling them to engage in daily physical activities that would otherwise cause pain.
XyloCor Therapeutics
Company Website: http://www.xylocor.com
Lead Product in Development: XC001

Company HQ City

Wayne

Company HQ State

PA

Company HQ Country

United States

CEO/Top Company Official

Al Gianchetti

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS